Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Mod...( SOUTH SAN FRANCISCO Calif. Jan. 1...),Health

SOUTH SAN FRANCISCO, Calif., Jan. 16 /PRNewswire/ -- Cerimon Pharmaceuticals, Inc., announced today it has initiated two randomized, double-blind, placebo-controlled Phase II/III clinical studies of its once- daily topical diclofenac sodium patch to treat mild to moderate pain. One of the studies, designated the "SUPPORT" (Stop Underlying Pain with a diclofenac Patch and Obtain Relief Topically) study, will assess the efficacy and safety of Cerimon's patch compared to placebo for the treatment of pain due to acute mild to moderate ankle sprains. The second study, designated the "ACTIVE" (A Clinical Trial to Investigate the effectiVEness of diclofenac pain patch) study, will assess the safety and efficacy of Cerimon's patch compared to placebo for the treatment of pain due to mild to moderate tendonitis or bursitis of the shoulder, elbow, or wrist. Each study will enroll over 300 subjects, with 50 percent of the subjects randomized to receive the diclofenac sodium patch and the other half to receive placebo.

Paul J. Sekhri, President and CEO of Cerimon Pharmaceuticals, stated, "Our diclofenac patch is designed to offer convenient, site-specific pain relief to patients with mild to moderate forms of musculoskeletal pain without systemic side effects associated with currently available oral NSAIDs. Consumers in Japan and several other countries have responded strongly to the advantages of topical diclofenac patches virtually identical to our patch, and we believe this provides an indication of the potential market demand in the U.S. Cerimon is moving its program forward aggressively to address this unmet medical need, allowing us to build a leadership position in the US pain market."

This is the second late-stage development program Cerimon commenced in the past year. In April 2007, the Company initiated a Phase IIb study of Simulect(R) (basiliximab) for moderate-to-severe steroid-refractory ulcerative colitis.

Pain Market

Musculoskel
'/>"/>